Shattuck Labs, Inc. (STTK)Healthcare | Biotechnology | Austin, United States | NasdaqGS
6.43 USD
-0.21
(-3.163%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 6.43 |
Hot Take ↕ | July 11, 2026, 7:04 a.m. EDT
The investment case for Shattuck Labs is fundamentally broken by a catastrophic multi-year decline. Despite a recent technical bounce off the lows, the business has lost nearly 97% of its value over the last four years, with revenue per share collapsing to negligible levels ($0.012) and operating margins remaining deeply negative (-52%). The balance sheet shows massive free cash burn (-$22M) against minimal cash reserves, indicating a desperate need for capital that is not being met by organic growth. While the stock has rallied recently, this appears to be a dead-cat bounce driven by speculative trading rather than a turnaround in fundamentals. The lack of dividends and the severe deterioration in profitability make this a clear avoid for long-term investors. Short-term traders may see volatility, but the structural damage to the company's financial health is undeniable. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.184127 |
| AutoETS | 0.188574 |
| AutoTheta | 0.205888 |
| AutoARIMA | 0.341038 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 3.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.120 |
| Excess Kurtosis | -0.81 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.015 |
| Revenue per Share | 0.012 |
| Market Cap | 614,117,504 |
| Forward P/E | -12.47 |
| Beta | 1.06 |
| Website | https://www.shattucklabs.com |
As of July 11, 2026, 7:04 a.m. EDT: Speculators are positioned defensively with heavy open interest in deep out-of-the-money puts (strikes significantly below current price) expiring in late 2026, while call activity is sparse and concentrated near the money. Implied volatility is elevated for near-term protection, suggesting a fear of further downside rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 7.097561 |
| Address1 | 500 West 5th Street |
| Address2 | Suite 1200 |
| All Time High | 60.516 |
| All Time Low | 0.692 |
| Ask | 8.1 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 2,525,800 |
| Average Daily Volume3 Month | 1,064,081 |
| Average Volume | 1,064,081 |
| Average Volume10Days | 2,525,800 |
| Beta | 1.061 |
| Bid | 4.68 |
| Bid Size | 2 |
| Book Value | 1.268 |
| City | Austin |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.43 |
| Current Ratio | 22.065 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 6.63 |
| Day Low | 6.2512 |
| Debt To Equity | 3.015 |
| Display Name | Shattuck Labs |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -48,940,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -8.286 |
| Enterprise To Revenue | 405.526 |
| Enterprise Value | 405,525,728 |
| Eps Current Year | -0.50052 |
| Eps Forward | -0.51568 |
| Eps Trailing Twelve Months | -0.56 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.9624 |
| Fifty Day Average Change | 0.46759987 |
| Fifty Day Average Change Percent | 0.078424774 |
| Fifty Two Week Change Percent | 709.7561 |
| Fifty Two Week High | 8.33 |
| Fifty Two Week High Change | -1.9000001 |
| Fifty Two Week High Change Percent | -0.22809125 |
| Fifty Two Week Low | 0.712 |
| Fifty Two Week Low Change | 5.718 |
| Fifty Two Week Low Change Percent | 8.030899 |
| Fifty Two Week Range | 0.712 - 8.33 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,602,250,200,000 |
| Float Shares | 46,847,962 |
| Forward Eps | -0.51568 |
| Forward P E | -12.468972 |
| Free Cashflow | -22,423,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 40 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -2.978 |
| Gross Profits | -2,978,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04531 |
| Held Percent Institutions | 0.59558 |
| Implied Shares Outstanding | 95,508,165 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-10-09 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas. |
| Long Name | Shattuck Labs, Inc. |
| Market | us_market |
| Market Cap | 614,117,504 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_378179277 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -49,874,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 632,741,593 |
| Number Of Analyst Opinions | 6 |
| Open | 6.63 |
| Operating Cashflow | -41,274,000 |
| Operating Margins | -52.582996 |
| Payout Ratio | 0.0 |
| Phone | 512 900 4690 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 6.43 |
| Post Market Time | 1,783,973,405 |
| Previous Close | 6.64 |
| Price Eps Current Year | -12.84664 |
| Price Hint | 2 |
| Price To Book | 5.0709777 |
| Price To Sales Trailing12 Months | 614.1175 |
| Profit Margins | 0.0 |
| Quick Ratio | 21.28 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.21 |
| Regular Market Change Percent | -3.16265 |
| Regular Market Day High | 6.63 |
| Regular Market Day Low | 6.2512 |
| Regular Market Day Range | 6.2512 - 6.63 |
| Regular Market Open | 6.63 |
| Regular Market Previous Close | 6.64 |
| Regular Market Price | 6.43 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 863,351 |
| Return On Assets | -0.36661 |
| Return On Equity | -0.61037 |
| Revenue Per Share | 0.012 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 95,508,165 |
| Shares Percent Shares Out | 0.0621 |
| Shares Short | 5,929,245 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,148,683 |
| Short Name | Shattuck Labs, Inc. |
| Short Percent Of Float | 0.0644 |
| Short Ratio | 3.21 |
| Source Interval | 15 |
| State | TX |
| Symbol | STTK |
| Target High Price | 18.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 14.83333 |
| Target Median Price | 16.0 |
| Total Cash | 90,419,000 |
| Total Cash Per Share | 1.179 |
| Total Debt | 2,889,000 |
| Total Revenue | 1,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.4565 |
| Two Hundred Day Average Change | 1.9734998 |
| Two Hundred Day Average Change Percent | 0.44283625 |
| Type Disp | Equity |
| Volume | 863,351 |
| Website | https://www.shattucklabs.com |
| Zip | 78,701 |